Targeted Delivery of Silver Nanoparticles and Alisertib:
            <i>In Vitro</i>
            and
            <i>In Vivo</i>
            Synergistic Effect Against Glioblastoma

Locatelli, Erica; Naddaka, Maria; Uboldi, Chiara; Loudos, George; Fragogeorgi, Eirini; Molinari, V.; Pucci, Andrea; Tsotakos, Theodoros; Psimadas, Dimitrios; Ponti, Jessica; Franchini, Mauro Comes

doi:10.2217/nnm.14.1

Cited by 143 publications

(82 citation statements)

References 42 publications

(39 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[1][2][3] Among nanomaterials, silver nanoparticles (AgNPs) are the most widely applied for both commercial and clinical biomedical applications. 4 Preclinical studies on AgNPs show that they possess cytotoxic activity toward a variety of cancer cell lines, including breast, [5][6][7] glioblastoma, [8][9][10] cervical, 11 liver, 12 lung, 13 and leukemia. 14,15 The ability of AgNPs to act as radiosensitizers has been observed for the treatment of glioma, 10,16 gastric cancer, 17 and breast cancer.…”

Section: Introductionmentioning

confidence: 99%

Differential cytotoxic and radiosensitizing effects of silver nanoparticles on triple-negative breast cancer and non-triple-negative breast cells

Swanner¹,

Mims²,

Carroll³

et al. 2015

IJN

View full text Add to dashboard Cite

Identification of differential sensitivity of cancer cells as compared to normal cells has the potential to reveal a therapeutic window for the use of silver nanoparticles (AgNPs) as a therapeutic agent for cancer therapy. Exposure to AgNPs is known to cause dose-dependent toxicities, including induction of oxidative stress and DNA damage, which can lead to cell death. Triple-negative breast cancer (TNBC) subtypes are more vulnerable to agents that cause oxidative stress and DNA damage than are other breast cancer subtypes. We hypothesized that TNBC may be susceptible to AgNP cytotoxicity, a potential vulnerability that could be exploited for the development of new therapeutic agents. We show that AgNPs are highly cytotoxic toward TNBC cells at doses that have little effect on nontumorigenic breast cells or cells derived from liver, kidney, and monocyte lineages. AgNPs induced more DNA and oxidative damage in TNBC cells than in other breast cells. In vitro and in vivo studies showed that AgNPs reduce TNBC growth and improve radiation therapy. These studies show that unmodified AgNPs act as a self-therapeutic agent with a combination of selective cytotoxicity and radiation dose-enhancement effects in TNBC at doses that are nontoxic to noncancerous breast and other cells.

show abstract

Section: Introductionmentioning

confidence: 99%

Differential cytotoxic and radiosensitizing effects of silver nanoparticles on triple-negative breast cancer and non-triple-negative breast cells

Swanner¹,

Mims²,

Carroll³

et al. 2015

IJN

View full text Add to dashboard Cite

show abstract

“…In addition, the possibility to use a wide range of ligands for the ne tuning of the complexes physical and chemical properties together with intense, long-living, and environment-sensitive emission, permit their employment as reporters of their local surroundings and intracellular biological events. 18 Following our long-standing interest in GBM, we have recently validated the use of the chlorotoxin (Cltx) peptide, as a suitable in vitro 19,20 and in vivo 21,22 targeting agents for glioma cell lines. This problem can be prevented by the incorporation and/or linkage of the luminescent derivatives into biologically compatible nanocarriers, through covalent or non-covalent interactions.…”

Section: Introductionmentioning

confidence: 99%

Hybrid cholesterol-based nanocarriers containing phosphorescent Ir complexes: in vitro imaging on glioblastoma cell line

et al. 2015

Self Cite

View full text Add to dashboard Cite

Recently the use of phosphorescent heavy-metal complexes in bioimaging techniques has been a promising research field and has been attracted increasing interest. Among these, phosphorescent iridium(III) complexes have shown many photophysical characteristics that made them promising candidates for fluorescence probes. In this study an innovative copolymer consisting of cholesterol, a natural component of biological membranes, and the well-known biocompatible Polyethylene (PEG), has been synthesized. Cholesterol-PEG amphiphilic copolymer has been used to form novel nanocarriers characterized by the incorporation and/or linkage of the phosphorescent iridium(III) derivatives through covalent or non-covalent interactions. Finally the nanocarrier's surface has been functionalized with the peptide chlorotoxin (Cltx), a targeting agent selective for glioblastoma cells (U87MG). The so obtained targeted water soluble nanocarrier has been tested for in vitro imaging on the glioblastoma cell line and has shown no toxic effect on cells.

show abstract

“…[110] Contortrostatin, a snake venom disintegrin, was proven to inhibit tumor growth and angiogenesis and to prolong survival in a rodent glioma model by Pyrko et al [111] Similarly, scorpion venoms has been used in targeting brain tumors, in tumor painting, and in cell sensitization to chemotherapy. [112][113][114] Chlorotoxin (CTX) is a promising tool for glioma management. [112,[115][116][117][118] Chlorotoxin binds to metallomatrix proteins-2 and a gliomaspecific chloride channel.…”

Section: Solid Lipid Nanoparticlesmentioning

confidence: 99%

Tailored nanocarriers and bioconjugates for combating glioblastoma and other brain tumors

ElAmrawy¹,

Othman²,

Adkins³

et al. 2016

JCMT

View full text Add to dashboard Cite

Worldwide, the incidence of primary brain tumors is on the rise. Unfortunately, noninvasive drug therapy is hampered by poor access of most drugs to the brain due to the insurmountable blood-brain barrier (BBB). Nanotechnology holds great promise for noninvasive therapy of severe brain diseases. Furthermore, recent bioconjugation strategies have enabled the invasion of the BBB via tailored-designed bioconjugates either with targeting moieties or alterations in the physicochemical and/or the pharmacokinetic parameters of central nervous system (CNS) active pharmaceutical ingredients. Multifunctional systems and new entities are being developed to target brain cells and tumor cells to resist the progression of brain tumors. Direct conjugation of an FDA-approved drug with a targeting moiety, diagnostic moiety, or pharmacokinetic-modifying moiety represents another current approach in combating brain tumors and metastases. Finally, genetic engineering, stem cells, and vaccinations are innovative nontraditional approaches described in different patents for the management of brain tumors and metastases. This review summarizes the recent technologies and patent applications in the past five years for the noninvasive treatment of glioblastoma and other brain tumors. Till now, there has been no optimal strategy to deliver therapeutic agents to the CNS for the treatment of brain tumors and metastases. Intensive research efforts are ongoing to bring novel CNS delivery systems to potential clinical application.

show abstract

Targeted Delivery of Silver Nanoparticles and Alisertib: In Vitro and In Vivo Synergistic Effect Against Glioblastoma

Cited by 143 publications

References 42 publications

Differential cytotoxic and radiosensitizing effects of silver nanoparticles on triple-negative breast cancer and non-triple-negative breast cells

Differential cytotoxic and radiosensitizing effects of silver nanoparticles on triple-negative breast cancer and non-triple-negative breast cells

Hybrid cholesterol-based nanocarriers containing phosphorescent Ir complexes: in vitro imaging on glioblastoma cell line

Tailored nanocarriers and bioconjugates for combating glioblastoma and other brain tumors

Contact Info

Product

Resources

About